Translating world leading research in NMT into novel medicines
Myricx Pharma (“Myricx”) is a small molecule drug discovery company engaged in developing novel proprietary inhibitors of human N-myristoyltransferases (NMT), with a primary focus in oncology but also exploring potential applications across viral and other diseases.
The Company is based on novel discoveries from the research laboratories of its co-founders, Prof Ed Tate, Dr Roberto Solari and Dr Andrew Bell. The research teams identified that inhibition of NMT, an enzyme involved in myristoylation of certain proteins, results in specific cancer cell killing via an unexpected and unique mechanism. This breakthrough discovery reveals that NMT inhibitors are proving to be highly effective in the treatment of MYC-driven cancer models. Until now MYC was considered to be undruggable. Myricx is now prioritising the development of potent small-molecule inhibitors with the aim of building a proprietary pipeline of targeted cancer therapies.
Intellectual Property
Myricx has rights to key NMT discoveries, and composition-of-matter and use patents of its scientific co-founders through exclusive license agreements with Imperial College London.
Business Model
Based on a semi-virtual operating model, we outsource activities beyond the Company’s core capabilities to leading chemistry and pre-clinical contract research organisations.
Investors
A private company, Myricx is backed by a syndicate of experienced investors including Brandon Capital Partners and Sofinnova Partners.
